SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Organovo Holdings, Inc. – ‘8-K’ for 2/8/12 – EX-10.13

On:  Monday, 2/13/12, at 5:13pm ET   ·   For:  2/8/12   ·   Accession #:  1213900-12-621   ·   File #:  333-169928

Previous ‘8-K’:  ‘8-K’ on 2/3/12 for 1/30/12   ·   Next:  ‘8-K’ on / for 2/14/12   ·   Latest:  ‘8-K’ on 4/23/24 for 4/19/24   ·   18 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 2/13/12  Organovo Holdings, Inc.           8-K:1,2,3,4 2/08/12   30:6.0M                                   Edgar Agents LLC/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML   1.17M 
 2: EX-2.1      Merger Agreement                                    HTML    647K 
 3: EX-2.2      Certificate of Merger                               HTML     24K 
 4: EX-4.1      Bridge Warrant                                      HTML     99K 
 5: EX-4.2      Bridge Note                                         HTML     58K 
 6: EX-4.3      Instrument Defining the Rights of Security Holders  HTML    157K 
 7: EX-4.4      Ppo Investor Warrant                                HTML    105K 
 8: EX-4.5      Exchange Warrant                                    HTML    140K 
 9: EX-4.6      Bridge Exchange Warrant                             HTML     97K 
10: EX-4.7      Form of Lock-Up                                     HTML     22K 
11: EX-10.1     Bridge Spa                                          HTML    102K 
13: EX-10.10    General Release Agreement                           HTML     27K 
14: EX-10.11    Share Cancellation Agreement                        HTML     19K 
15: EX-10.12    B Michaels Offer Lette                              HTML     24K 
16: EX-10.13    Presnell Offer Letter                               HTML     25K 
17: EX-10.14    2008 Equity Incentive Plan                          HTML    149K 
18: EX-10.15    2012 Equity Incentive Plan                          HTML    125K 
19: EX-10.16    Form of Stock Option Agreement                      HTML     59K 
20: EX-10.17    Indemnification Agreemeent                          HTML     74K 
21: EX-10.18    Baltera Mou                                         HTML     21K 
22: EX-10.19    Prestwich Sab Agreement                             HTML     51K 
23: EX-10.20    Mooney Sab Agreement                                HTML     58K 
24: EX-10.21    Vunjak-Novakovic Sab Agreement                      HTML     51K 
25: EX-10.22    Kent Sab Agreement                                  HTML     55K 
26: EX-10.23    License Agreement                                   HTML     80K 
27: EX-10.24    License Agreement                                   HTML     79K 
28: EX-10.25    License Agreement                                   HTML    233K 
12: EX-10.9     Split-Off Agreement                                 HTML    112K 
29: EX-16.1     Letter Re Change in Certifying Accountant           HTML     14K 
30: EX-21.1     Subsidiaries of Organovo Holdings, Inc.*            HTML      9K 


EX-10.13   —   Presnell Offer Letter


This exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



Exhibit 10.13
  Organovo, Inc.
  5871 Oberlin Dr. Suite 150
  San Diego, CA 92121
 
Sharon Presnell
705 River Grove Ct.
Lewisville, NC 27023
 
April 4, 2011

Dear Sharon,
 
I am pleased to offer you a position at Organovo, Inc. as Executive Vice President of Research and Development, reporting to Keith Murphy, Chief Executive Officer.  The compensation and benefits for this position are as follows, subject to the policies of the company.
 
Salary: A base salary of$248,014 per annum, paid as a biweekly installment of $9,539.00, subject to deductions and income tax withholding as required by law or the policies of the company.  Additionally, this position is eligible for an annual bonus calculated as a proportion of annual earnings, targeted at 30% but adjustable up or down based on individual and company performance.  The bonus awarded will be based on factors such as the achievement of corporate and individual goals each calendar year.  The annual bonus shall not be contingent upon non-dilutive grant monies arranged for the company, but the minimum bonus amount payable on the first anniversary of hire shall be $35,000 per $1,000,000 of non-dilutive grant monies actually received by the company during the first year of employment, and the minimum bonus amount payable on the second anniversary of hire shall be $35,000 per $1,000,000 of non-dilutive grant monies actually received by the company during the second year of employment.
 
Equity Package: Subject to the approval of Organovo's Board of Directors and awarded on the date of such approval, a stock option award equivalent to 4% of Organovo, Inc. stock, with a vesting period of 4 years, subject to the terms and conditions of the Organovo, Inc. 2008 Equity Incentive Plan and subsequent to stock splits and dilution of current shares outstanding.
 
Benefits:  Company health, dental, and vision insurance coverage are supplied. Organovo will cover costs required for an individual or group medical plan, or reimburse you for costs associated with an election to continue benefits under your current plan, at the company's discretion.  Spousal and dependent coverage is provided.  Eligibility for other benefits, including benefits that might be offered in the future will generally take place per company policy.  Employee contribution to payment for benefit plans, if any, is determined annually.
 
Vacation and Personal Time Off: Vacation and personal time is accrued at 4.6 hours per pay period, which is equivalent to fifteen (15) days for a full time employee on an annual basis, and will increase over time per company policy.
 
Relocation expenses: A maximum allowance of $42,000 for relocation expenses. The allowance will be in the form of$18,000 in up front reimbursable costs and up to $2,000 per month for up to 12 months subsequent to hiring.  Employee will cover all expenses beyond this level.
 
 
 

 
 
Severance: If your employment is terminated by the Company for reasons other than cause at any time after the ninety (90) days following the date upon which you commence employment, Organovo will provide you with a severance package to assist you through your transition period.  Such severance package will be paid as follows: if you execute and deliver to the Company the Company's form of Release and Non-disparagement Agreement for departing employees within the time-frame contemplated by that document, you will receive three (3) months of salary and benefits plus an additional two (2) weeks of salary and benefits for each full year of employment, up to a maximum of six (6) months of total salary and benefits paid, to be paid in substantially the same manner and form as the Company provided such salary and benefits to you prior to termination. The severance will continue for the period entitled to you as described above unless you begin other employment during that period, in which case the severance shall be paid through the business day preceding the initiation of employment.  Should your employment be terminated by the Company for Cause, or if you resign or your employment is terminated by reason of your death, you will not be entitled to a severance package.
 
Start Date:  The start date for this position will be no later than Monday, May 2.
 
Your employment offer is contingent upon the completion of a Confidentiality Agreement with the Company.  Your employment is at-will and either party can terminate the relationship at any time with or without cause and with or without notice.
 
You acknowledge that this offer letter represents the entire agreement between you and Organovo, Inc. and that no verbal or written agreements, promises or representations that are not specifically stated in this offer, are or will be binding upon Organovo, Inc.  If you are in agreement with the above outline, please sign below. This offer is in effect for three business days.
 
We at Organovo, Inc. hope that you'll accept this job offer and look forward to welcoming you aboard!  Please feel free to call me if you have any questions.
 
  Sincerely,  
     
  /s/ Keith Murphy  
  Keith Murphy  
  Chief Executive Officer  
  Organovo, Inc.  
 
To accept this job offer, sign and date this job offer letter where indicated below.
 
Return a signed and dated document back by April 7, 2011. A copy of the document should be retained for your records.  Please use the following information to send the document:
 
If you choose to send via mail, please send to the following address:
Organovo, Inc.
Attn: Keith Murphy
5871 Oberlin Dr. Suite 150
San Diego, CA 92121
 

Accepting Job Offer
By signing and dating this letter below, I, Sharon Presnell, accept this offer of employment from
 
Organovo, Inc.
 
Signature: /s/ Sharon Presnell   Date: 4/7/2011
         
         
                                                       
 
                               

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on:2/13/12
For Period End:2/8/128-K/A
4/7/11S-1/A
4/4/11
 List all Filings 


18 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/12/24  Organovo Holdings, Inc.           S-1                   76:11M                                    Donnelley … Solutions/FA
 7/31/23  Organovo Holdings, Inc.           10-K/A      3/31/23   12:1.4M                                   Donnelley … Solutions/FA
 7/14/23  Organovo Holdings, Inc.           10-K        3/31/23   75:12M                                    Donnelley … Solutions/FA
10/25/22  Organovo Holdings, Inc.           S-8 POS    10/25/22    3:103K                                   Donnelley … Solutions/FA
10/25/22  Organovo Holdings, Inc.           S-8 POS    10/25/22    3:103K                                   Donnelley … Solutions/FA
10/25/22  Organovo Holdings, Inc.           S-8 POS    10/25/22    3:103K                                   Donnelley … Solutions/FA
10/25/22  Organovo Holdings, Inc.           S-8 POS    10/25/22    3:103K                                   Donnelley … Solutions/FA
10/25/22  Organovo Holdings, Inc.           S-8 POS    10/25/22    3:103K                                   Donnelley … Solutions/FA
 6/10/22  Organovo Holdings, Inc.           10-K        3/31/22   76:8.3M                                   ActiveDisclosure/FA
11/09/21  Organovo Holdings, Inc.           S-8        11/09/21    3:88K                                    Donnelley … Solutions/FA
 7/29/21  Organovo Holdings, Inc.           10-K/A      3/31/21   12:1.3M                                   ActiveDisclosure/FA
 6/15/21  Organovo Holdings, Inc.           10-K        3/31/21   74:7.1M                                   ActiveDisclosure/FA
 9/17/20  Organovo Holdings, Inc.           8-K:5,9     9/15/20    1:127K                                   ActiveDisclosure/FA
 9/03/20  Organovo Holdings, Inc.           DEFA14A     9/03/20    1:120K                                   ActiveDisclosure/FA
 9/03/20  Organovo Holdings, Inc.           8-K:3,5,9   9/02/20    2:85K                                    ActiveDisclosure/FA
 6/21/12  SEC                               UPLOAD10/03/17    1:45K  Organovo Holdings, Inc.
 4/18/12  SEC                               UPLOAD10/03/17    1:55K  Organovo Holdings, Inc.
 3/13/12  SEC                               UPLOAD10/03/17    1:61K  Organovo Holdings, Inc.
Top
Filing Submission 0001213900-12-000621   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., Apr. 30, 3:46:27.1am ET